Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina.

MV, Martire; J, Marin; H, Maldonado-Ficco; M, Benegas; P, Giorgis; D, Vila; CA, Isnardi; MJ, Gamba; JF, Flores-Trejo; R, Perez-Alamino; AJ, Chemez; L, Ferreyra-Garrott; MA, Cosatti; EA, Buschiazzo; Los Angeles Correa M, de; R, Aguila-Maldonado; B, Manases-Roldan; C, Lizarraga; MA, Alfaro; J, Morbiducci; LV, Ingolotti; G, Pendón; RE, Nieto; MS, Velloso; A, Martinez-Muñoz; N, Lloves-Schenone; NV, Zamora; E, Saturansky; AC, Costi; MJ, Haye-Salinas; CA, Airoldi; A, Granel

doi:10.3899/jrheum.2024-1185

Public

Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina.

Shared by NobleBlocks on Aug 1, 2025 • 12:00 AM UTC

Authors:

Martire MV

Marin J

Maldonado-Ficco H

Abstract

Objective To describe the access, effectiveness, survival, and adverse events (AEs) of secukinumab (SEC) in patients with axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA).Methods In a multicenter, observational, retrospective cohort study, patients ≥ 18 years with axSpA or axPsA...

Subject

Psoriatic Arthritis

Axial Spondyloarthritis

Drug Survival

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!